Trial Profile

A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melphalan (Primary)
Indications Liver metastases; Uveal melanoma
Focus Registrational; Therapeutic Use
Acronyms FOCUS
Sponsors Delcath Systems

Most Recent Events

09 Apr 2025 Results published in the Delcath Systems Media Release.
09 Apr 2025 According to a Delcath Systems media release, the company has published a comparative analysis from the randomized cohort of this study in Annals of Surgical Oncology.
16 Sep 2024 According to a Delcath Systems media release, data from this trial presented at the ESMO conference 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com